For diabetes care and education specialists, late April and early May have ushered in a whirlwind of knowledge and advances. ATTD 2022 marked the start of a conference season that includes meetings hosted by the American Association of Clinical Endocrinology (AACE), the American Diabetes Association (ADA), and the Endocrine Society within a 48-day span. Add to this, news surrounding the US FDA’s approval of Eli Lilly and Company’s novel dual GIP/GLP-1 receptor agonist, tirzepatide, and the full docket of news and information to download from this brief period becomes clear.
In this episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the tirzepatide approval, including discussions around the mechanism of action for the first-in-class agent, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of guidelines for diagnosis and management of nonalcoholic fatty liver disease (NAFLD) in primary care and endocrinology clinical settings.
Check out previous episodes of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, including a recap of the 15th International Conference on Advanced Technologies and Treatments for Diabetes.